Health – Signing of a license by the Medicines Patent Pool for a hepatitis C medication (November 23, 2015)

We applaud the royalty-free license signed by the pharmaceutical company Bristol-Myers-Squibb and the Medicines Patent Pool established by UNITAID.

Daclastavir, an effective antiviral for hepatitis C, can now be manufactured as a generic drug in 112 low- and middle-income countries that are home to nearly two-thirds of those living with this disease.

In 2010, UNITAID, to which France is the leading donor, created the patent pool to lower the cost of HIV treatments and facilitate the development of appropriate drugs through voluntary agreements and patent-sharing.

Coming less than three weeks after UNITAID’s decision to use the patent pool to combat hepatitis C and tuberculosis, this agreement represents a major step forward in helping patients on all continents.